Showing results (471-480 of 538) with videos related to

Sort By:
Pageof 54
Headache|April 1, 2022
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative reviewDavid W Dodick, Peter J Goadsby, Messoud Ashina, et al.
Cephalalgia : an International Journal of Headache|March 9, 2011
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraineDavid J Hewitt, Sheena K Aurora, David W Dodick, et al.
The Lancet. Neurology|June 14, 2024
Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headacheAnja S Petersen, Nunu Lund, Peter J Goadsby, et al.
Headache|June 3, 2021
Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequencyRyotaro Ishii, Todd J Schwedt, Gina Dumkrieger, et al.
SLAS Technology|September 21, 2025
Single-step purification and formulation of antibody-drug conjugates using a miniaturized tangential flow filtration systemMuhammad Sajed, Zahoor Khan, Muhammad Usman Ashraf, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|December 11, 2008
Imaging patients with suspected brain tumour: guidance for primary careDavid P Kernick, Fayyaz Ahmed, Anish Bahra, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Cephalalgia : an International Journal of Headache|February 14, 2020
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatmentDavid W Dodick, Peter J Goadsby, Christian Lucas, et al.
JAMA Neurology|December 20, 2017
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical TrialVladimir Skljarevski, Tina M Oakes, Qi Zhang, et al.
Neurology|April 29, 2021
Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY StudyPeter J Goadsby, Uwe Reuter, Michel Lanteri-Minet, et al.
Pageof 54